Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Mechanisms of resistance to targeted tyrosine kinase inhibitors
Stacey J. Baker
,
E. Premkumar Reddy
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Mechanisms of resistance to targeted tyrosine kinase inhibitors'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Lung Cancer
100%
Kinase Inhibitor
100%
Epidermal Growth Factor Receptor
100%
Chronic Myeloid Leukemia
100%
Philadelphia Chromosome
100%
Small Molecules
100%
Resistance Mechanisms
100%
Gefitinib
100%
Tyrosine Kinase Inhibitor
100%
Malignant Transformation
100%
Erlotinib
100%
Kinase Domain
100%
Gleevec
100%
BCR-ABL
100%
Imatinib
100%
STI571
100%
Targeted Inhibitors
100%
Unwanted Side Effects
100%
Multikinase Inhibitor
100%
Tyrosine Kinase Oncogene
100%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Tyrosine Kinase Inhibitor
100%
Imatinib
100%
Phosphotransferase Inhibitor
66%
Malignant Neoplasm
33%
Phosphotransferase
33%
Protein Tyrosine Kinase
33%
Carcinogenesis
33%
Lung Cancer
33%
Epidermal Growth Factor Receptor
33%
Gefitinib
33%
Chronic Myeloid Leukemia
33%
Erlotinib
33%
Philadelphia 1 Chromosome
33%
Malignant Transformation
33%
Diseases
33%
Side Effect
33%